Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Leiden University Medical Center
Massachusetts General Hospital
Delfi Diagnostics Inc.
Medipol University
Kayseri City Hospital
Navigation Sciences, Inc.
Philips Respironics
Hoffmann-La Roche
University of Alabama at Birmingham
Başakşehir Çam & Sakura City Hospital
Revolution Medicines, Inc.
Rigshospitalet, Denmark
Stanford University
University of Washington
VA Office of Research and Development
Ambu A/S
McGill University Health Centre/Research Institute of the McGill University Health Centre
Milton S. Hershey Medical Center
University Hospital Augsburg
Johannes Gutenberg University Mainz
Carebot s.r.o.
Revolution Medicines, Inc.
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
University of Alberta
University of Wisconsin, Madison
Erasme University Hospital
Checkpoint Therapeutics, Inc.
Qmed Consulting A/S
Syndax Pharmaceuticals
Post Graduate Institute of Medical Education and Research, Chandigarh
Institut Bergonié
Syndax Pharmaceuticals
Syndax Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of Louisville
Peking University People's Hospital
H. Lee Moffitt Cancer Center and Research Institute
University of Cologne
Mereo BioPharma
Hallym University Kangnam Sacred Heart Hospital
Jiangsu HengRui Medicine Co., Ltd.
University Health Network, Toronto
St. Joseph's Healthcare Hamilton
Shanghai Pulmonary Hospital, Shanghai, China
Radboud University Medical Center
Radboud University Medical Center
Maastricht University
National Institutes of Health Clinical Center (CC)